2.5 mg tablets are now available by prescription in pharmacies throughout Canada. This is important news for those suffering from migraines who are not receiving effective therapy at the current time.
FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults.
“The launch of FROVA in Canada is further proof of Teva Neuroscience's commitment to patients suffering from neurology disorders”, announced Dr. Jean Godin, General Manager, Teva Neuroscience Canada . “While there are other treatments currently available for patients with migraines, our research shows that many patients are not satisfied with the relief or tolerability offered by the current medications. FROVA has a unique profile that may benefit many patients.”
Dr. Marek Gawel, a neurologist at Sunnybrook Health Science Center as well as Women's College that specializes in treating patients with migraines, was involved in various clinical trials for the drug. “In clinical trials we have found that the drug offers some unique advantages not found in other triptans. FROVA provides lasting relief for migraines. This is supported in the Ryan1 publication which shows a low headache recurrence, ranging from 7% to 25%, which resulted in a 24-hour sustained response in up to 51% of patients taking FROVA. It is likely that the low rates of headache recurrence appear to be, at least in part, due to FROVA's long half-life of 26 hours. For patients who respond to the treatment, this means that almost half will be pain-free for a full 24 hours with few potential side effects.”
Headache Network Canada: www.headachenetwork.ca
American Headache Society: www.achenet.org
American Academy of Neurology: www.aan.com
